Arabic Arabic English English French French German German
dark

Inovio and AstraZeneca Terminate Six-Year-Old DNA Cancer Vaccine Program

Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Cures for the health insurance enrollment blues

Next Post

Masimo Launches Dual SET® Pulse Oximetry

Related Posts
Total
0
Share